SCLY

Across TCGA pan-cancer cohorts, SCLY mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SCLY data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SCLY mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SCLY expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where SCLY mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.876	0.578	<.001	34	view →
PDAC	OS	Tertile	III,IV	0.605	0.300	.008	30	view →
CCRCC	OS	Quartile	All	1.000	0.836	.007	29	view →
UCEC	DFS	Median	III,IV	0.468	0.902	.026	4	view →
GBM	DFS	Median	All	0.208	0.426	.008	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SCLY–LUAD (OS)

Open the LUAD breakdown →